NCT05652907Phase 2Terminated

Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Study sponsor: Quantum Biopharma

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-24Actual
Enrollment · participants2Actual
Source updated2026-04-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Targeted treatment effect of 30% decrease from baseline to Day 28 in the average daily pain intensity. After: Measure: Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain Intensity.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview